title: [Pharmacology of bone anabolic agents].
abstract: Bone is constantly remodeled to maintain its volume, structural integrity and strength Currently available bone anabolic agent is teriparatide. Teriparatide increases bone mass and strength via both remodeling-dependent and -independent mechanisms, although remodeling-dependent mechanism overweighs the other. Canonical Wnt signal plays an important role in enhancing osteoblast differentiation and bone formation, and its osteocyte-derived inhibitor, sclerostin, regulates bone formation via the regulation of Wnt signaling. Anti-sclerostin antibody stimulates Wnt signaling and enhances bone formation. Phase II clinical trials with anti-sclerostin antibodies, romosozumab and blosozumab, demonstrated a marked increase in bone mineral density after one year of treatment. The new modality of anabolic agents via remodeling-independent stimulation of bone formation may open up a new avenue for the treatment of osteoporosis.
authors.forename: Toshio
authors.initials: T
authors.lastname: Matsumoto
mesh_terms: D045930:Anabolic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016723:Bone Remodeling; D001842:Bone and Bones / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D010012:Osteogenesis; D010024:Osteoporosis / Q000188:drug therapy; D060449:Wnt Signaling Pathway
chemical_list: D045930:Anabolic Agents